Impact of etiotropic therapy on the immune status of patients with HIV infection and tuberculosis


Aim. To evaluate the impact of etiotropic therapy on the immunological efficiency of treatment in patients with HIV infection in relation to the presence of active tuberculosis (TB) and the baseline count of CD4+ lymphocytes. Subjects and methods. A total of 239 HIV-infected patients were examined and divided into 3 groups: 1) 103 HIV-infected patients with TB who received both anti-TB therapy (ATBT) and antiretroviral therapy (ART); 2) 46 HIV-infected patients with TB who did not receive ART during TB treatment; 3) 90 HIV-infected patients without TB who used ART for the first time. CD4+ lymphocyte counts were measured by flow cytofluorometry in all the patients before and 4 and 12 weeks after treatment. Results. Analysis of an increment in CD4+ lymphocyte counts in the HIV-infected patients with tuberculosis showed that those who had very low baseline CD4+ lymphocyte counts (median, 78 cells/µl) were noted to have significant positive changes (median, +146 cells/ µl) at 12 weeks of ART. Even without ART, effective ATBT in the patients with a well preserved immune system (>350 CD4+ cells/µl) in turn resulted in a substantial increase in CD4+ lymphocyte counts (median, +187 cells/µl following 12-week ATBT). At the same time, 10.9% of the patients showed a decrease in the baseline CD4+ lymphocyte counts during progression or delay in the tuberculosis process, which required that ART should be promptly performed. Conclusion. The investigation of the time course of changes in the increment of CD4+ lymphocyte counts revealed a swifter response to ART as their rapid increment in patients with coinfection (HIV infection concurrent with TB) than that in those with HIV monoinfection. When the baseline CD4+ lymphocyte counts are over 350 cells/µl, the start of ART should be delayed until TB treatment is completed.

About the authors

V N Zimina

A V Kravchenko


  1. Юрин О.Г., Кравченко А.В., Канестри В.Г. Лекарственная терапия ВИЧ-инфекции. В кн.: Покровский В.В. ВИЧ-инфекция и СПИД. Национальное руководство. М.: ГЭОТАР-Медиа; 2013.
  2. Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции: 2011. М.: Р. Валент; 2012.
  3. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю., Ермак Т.Н., Буравцова Е.В., Шахгильдян В.И., Козырина Н.В., Нарсия Р.С., Зимина В.Н., Покровская А.В., Ефремова О.С. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиология и инфекционные болезни. 2014;6(1):1-48.
  4. Туберкулез и ВИЧ-инфекция: ведение больных с коинфекцией. Клинический протокол для Европейского региона ВОЗ (обновленная версия 2013 г.). Доступно по: 218516/Management-of-tuberculosis-and-HIV-coinfection-Rus.pdf.
  5. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 7.1; November, 2014). European AIDS Clinical Society. Доступно по:
  6. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) November 14, 2014. Доступно по:
  7. Abdool Karim SS, Naidoo K, Grobler A. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697-706.
  8. Blanc FX, Sok T, Laureillard D, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-1481.
  9. Havlir DV, Kendall MA, Ive P, Luetkemeyer A, Swindells S, Kumwenda J, Qasba S, Hogg E. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-1490.
  10. Mfinanga SG., Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, Ezechi O, Connolly C, Kapotwe V. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomized, placebo-controlled trial. The Lancet Inf Dis. 2014;14(7):563—571.
  11. Федеральные клинические рекомендации по диагностике и лечению туберкулеза у ВИЧ-инфицированных (2014). Доступно по:



Abstract - 127


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2015 Zimina V.N., Kravchenko A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies